Alnylam Pharmaceuticals, Inc. (ALNY) — Current Report

AI-Powered SEC Filing Analysis

← All ALNY filings
Latest Current Report Filed: 2026-02-12

Key Insights

  • Alnylam Pharmaceuticals reported its Q4 2025 financial results, indicating the company's continued growth and strong performance.
  • The company did not disclose any material agreements, leadership changes, or other significant events that would be considered a major event.
  • Based on the information provided, there are no major red flags or concerns that would significantly impact the company's outlook or investor sentiment.
Filing tone (AI): Positive
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-02-12. In the app, any new 10-K, 10-Q or 8-K is analyzed the moment you open it.

Download on theApp Store Get it onGoogle Play
Get it on Google Play Open in app →

Earlier Current Report filings

Filed: 2026-01-12
  • Alnylam Pharmaceuticals announced its new five-year strategy, 'Alnylam 2030', indicating a long-term focus on growth and innovation.
  • The company reported preliminary Q4 2025 and full-year 2025 global net product revenues of approximately $995 million and $2,987 million, respectively, for its key products AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO.
  • Alnylam provided its 2026 product and pipeline goals, as well as full-year 2026 combined net product revenue guidance, suggesting confidence in future performance.
Filing tone (AI): Positive
View Original Filing →

Other reports for Alnylam Pharmaceuticals, Inc.

Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.